Operations

The acquisition includes several gummy products that are expected to begin launching in 2026.

The AI dilemma facing biopharma—and what’s at risk.

A comparison of 2024 and 2025 bio/pharma employment survey results indicates that industry professionals face eroding security, polarized satisfaction, and rising attrition risk.

The company composed a letter addressed to global governments to harness competitiveness and innovation to navigate the current global trade economy.

When approaching cell and gene therapies (CGT), investors want to back companies that demonstrate operational foresight. Here are five levers for building a CGT operating model that can tackle the category’s unique commercialization complexities.

Hoth Therapeutics has filed dual provisional patents positioning HT-001 as a potential first-in-class solution for managing treatment-induced skin toxicities across modern oncology therapies.

Jim Greffet, head of sustainability at Eli Lilly, on establishing ESG as a core business driver—and key complement to manufacturer long-term growth pursuits.

With patent cliffs fast approaching, asset differentiation will be king.

Amid the US reshoring push, drugmakers navigate geopolitical and supply chain risks.

Outlining the big questions and considerations for pharma companies in determining their readiness for this transformation—and achieving true “AI Advanced” status.

Welcome to Pharm Exec's new guest column on navigating the geopolitical risks challenging core company strategies in today's shifting global landscape for healthcare.

The agency also named a new head of its Office of Nonprescription Drugs.

The former FDA oncology chief is set to resign by the end of the month.

The agency says that the decision aims to improve employee workflow and build on its previously implemented generative AI tool Elsa.

Q&A with Krishna Kanumuri, CEO of Sai Life Sciences, on steering a contract development and management organization through growth, scale-up, and the shifting global supply chain in pharma.

Novartis is planing layoffs in Switzerland, along with plans to invest $80 million to enhance RNA treatment production and create new jobs by 2028.

Pharmaceutical collaborations expand as Flagship Pioneering expands its partnership with GSK, signing agreements with ProFound Therapeutics and Quotient Therapeutics, while Valo Health teams up with Merck KGaA to tackle disease challenges.

Abbott's acquisition of Exact Sciences enhances cancer diagnostics and expands access to innovative screening and treatment solutions for patients worldwide.

Johnson & Johnson aims to enhance its oncology portfolio and innovate prostate cancer treatments by expanding its therapeutic pipeline through the acquisition.

UnitedHealth Group appoints Dr. Scott Gottlieb to its board, enhancing leadership amongst a time in which the company looks to enhance its public outlook.

Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.

Organon faces leadership changes as CEO Kevin Ali resigns amid an investigation into improper sales practices involving Nexplanon.

The decision impacts hopes for preventing congenital infections, although the company is continuing other research initiatives.

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.